Do GLP-1 Drugs Change Your Resting Heart Rate?
*People watching their wearable numbers after starting a GLP-1 medication keep asking the same thing: is this rise real, and does it settle down.*
This article covers what wearable-tracked data has shown about resting heart rate changes after starting a GLP-1 receptor agonist. It does not cover dosing decisions, drug switching, or long-term cardiovascular outcomes beyond what the cited research measured.
A wearable-based tracking study following people for 12 weeks after they started a GLP-1 receptor agonist found resting heart rate went up, alongside significant weight loss, even though the group was compared against a matched control. That's the one study built to actually measure this in free-living people wearing consumer devices. It does not tell us whether the increase keeps climbing, plateaus, or reverses at different doses, because it wasn't designed to compare dose levels against each other.
What people on wearables are actually noticing
Scroll through enough GLP-1 discussion threads and a pattern shows up fast. Someone's resting heart rate has climbed into the 90s after starting the medication, and they're wondering if that's just how it goes. Someone else is watching for a skipped or early beat on their watch's ECG feature, wondering if that counts as normal. And a third person wants to know if the elevated heart rate they've read about as a side effect fades once the dose goes higher, or just sits there.
The common thread isn't panic, it's pattern-recognition. People are trying to figure out whether what their wearable is showing them is expected, temporary, or worth flagging.
Why the rise doesn't automatically mean something is wrong
It's tempting to read any wearable number that jumps as a warning. But what an elevated resting heart rate actually means depends heavily on context, and the GLP-1 study noted heterogeneity in cardiovascular responses across the people it tracked, not everyone's heart rate moved the same amount or in the same direction. The study was designed to isolate the medication's association with heart rate and behavior changes like activity and sleep, not to explain why any one person's number moved the way it did.
What the research doesn't establish is whether the increase seen at 12 weeks continues, stabilizes, or reverses beyond that window, the tracking just stopped there. It also doesn't compare people across different doses to see if a higher or lower amount changes the pattern, which is exactly what several people watching their own numbers want to know. On the general question of what resting heart rate levels mean for risk, a heart rate in the 60 to 80 bpm range carrying elevated mortality risk compared with lower resting rates in general population data is a separate, established finding, not something demonstrated specifically in GLP-1 users.
The wearable study behind this article tracked 66 people for 12 weeks. It did not compare different GLP-1 doses against each other, did not run past 12 weeks, and doesn't tell us whether heart rate changes settle, keep rising, or reverse with continued use beyond that window.
How this fits into the bigger resting heart rate picture
Resting heart rate on its own is one of the most studied vital signs there is, and the general population data on it runs much deeper than anything GLP-1-specific. A meta-analysis of prospective cohorts found each 10 beat per minute increase in resting heart rate was tied to roughly a 9 percent higher risk of all-cause mortality. A separate review has argued resting heart rate deserves more attention as both a prognostic marker and a potential therapeutic target in its own right. Neither study was about GLP-1 medications. They're about what resting heart rate levels tend to predict generally, useful context but not a direct answer to what's happening physiologically when someone starts a GLP-1 drug.
For anyone trying to make sense of a wearable trend line rather than a single reading, how wearables actually measure resting heart rate matters too, since device-level differences in how a low is calculated can shape what number shows up on a dashboard.
Common questions
Does resting heart rate really go up when starting a GLP-1 medication?
A wearable-tracked study following 66 adults for 12 weeks after starting a GLP-1 receptor agonist found resting heart rate increased compared with a matched control group, even as participants lost a substantial amount of weight. That's the specific finding from that study; it doesn't establish what happens for every individual or every medication in this class.
Does the heart rate increase get better at higher doses?
The available wearable-based study tracked people over a fixed 12-week window and did not compare outcomes across different dose levels, so there isn't direct evidence one way or the other on whether higher doses change the pattern.
Is an elevated resting heart rate on a GLP-1 medication dangerous?
General population research links sustained higher resting heart rate to greater mortality risk, but that data isn't specific to people on GLP-1 medications, and questions about symptoms like palpitations or irregular beats are a matter for a doctor to evaluate directly.
How long was heart rate tracked in the GLP-1 wearable study?
Participants were tracked for the week before starting the medication through 12 weeks afterward. The study does not report what happens to resting heart rate beyond that period.
Sources
- Heart and health behavior responses to GLP-1 receptor agonists: a 12-wk study using wearable technology and causal inference.
- Suboptimal heart rate control despite beta-blocker use in coronary artery disease: evidence from the Fasa PERSIAN cohort.
- Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis.
- Resting heart rate in cardiovascular disease.